Last reviewed · How we verify

Sham Bimatoprost SR — Competitive Intelligence Brief

Sham Bimatoprost SR (Sham Bimatoprost SR) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prostaglandin analog. Area: Ophthalmology.

phase 3 Prostaglandin analog Prostaglandin receptor Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Sham Bimatoprost SR (Sham Bimatoprost SR) — AbbVie. Sham Bimatoprost SR is a prostaglandin analog that mimics the action of prostaglandin F2-alpha.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Sham Bimatoprost SR TARGET Sham Bimatoprost SR AbbVie phase 3 Prostaglandin analog Prostaglandin receptor
Cytotec Misoprostol Pfizer marketed NSAID combined with prostaglandin analog Cyclooxygenase (COX-1 and COX-2); Prostaglandin receptors 1988-01-01
Medical abortion Medical abortion Reproductive Health Training Center of the Republic of Moldova marketed Progesterone receptor antagonist + prostaglandin analog combination Progesterone receptor (PR); prostaglandin receptors (EP1, EP2, EP3, FP)
Misoprostol + vasopressin Misoprostol + vasopressin University Hospital of the West Indies marketed Combination therapy: prostaglandin analog + vasopressor Prostaglandin receptor (EP3/EP4) and vasopressin V1 receptor
Latanoprost plus adjunctive glaucoma medication Latanoprost plus adjunctive glaucoma medication Sight Sciences, Inc. marketed Prostaglandin analog with adjunctive glaucoma agent FP prostaglandin receptor (latanoprost component); adjunctive target unknown
Niacin/ Laropiprant Niacin/ Laropiprant Ludwig-Maximilians - University of Munich marketed Lipid-modifying agent; prostaglandin D2 receptor antagonist DGAT2 (niacin); DP1 prostaglandin receptor (laropiprant)
Travoprost/timolol fixed combination, travoprost Travoprost/timolol fixed combination, travoprost Aristotle University Of Thessaloniki marketed Prostaglandin analog / beta-blocker combination FP prostaglandin receptor (travoprost); beta-adrenergic receptors (timolol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prostaglandin analog class)

  1. Allergan · 3 drugs in this class
  2. AbbVie · 2 drugs in this class
  3. Bnai Zion Medical Center · 1 drug in this class
  4. Ibis Reproductive Health · 1 drug in this class
  5. Ocuwize LTD · 1 drug in this class
  6. Shaare Zedek Medical Center · 1 drug in this class
  7. University Medical Centre Maribor · 1 drug in this class
  8. University of North Carolina, Chapel Hill · 1 drug in this class
  9. University of Pennsylvania · 1 drug in this class
  10. Wolfson Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sham Bimatoprost SR — Competitive Intelligence Brief. https://druglandscape.com/ci/sham-bimatoprost-sr. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: